Search research articles
Contact Us
Filters
Showing results (221-230 of 317) with videos related to
Page
of 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations
Christian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
British Journal of Cancer
|
March 16, 2021
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis
Jesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry
Jesper van Breeschoten, Alfons J M van den Eertwegh, Doranne L Hilarius, et al.
JAMA Oncology
|
January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial
Alexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Alexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
NEJM Evidence
|
February 6, 2024
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
Alexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
Cancer
|
January 10, 2024
BRAF/MEK inhibitor rechallenge in advanced melanoma patients
Olivier J Van Not, Alfons J M van den Eertwegh, John B Haanen, et al.
British Journal of Cancer
|
March 8, 2022
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis
Jesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
Data in Brief
|
November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Page
of 32
Search research articles
Search
Showing results (221-230 of 317) with videos related to
Sort By:
Page
of 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations
Christian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
British Journal of Cancer
|
March 16, 2021
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis
Jesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry
Jesper van Breeschoten, Alfons J M van den Eertwegh, Doranne L Hilarius, et al.
JAMA Oncology
|
January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial
Alexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Alexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
NEJM Evidence
|
February 6, 2024
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
Alexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
Cancer
|
January 10, 2024
BRAF/MEK inhibitor rechallenge in advanced melanoma patients
Olivier J Van Not, Alfons J M van den Eertwegh, John B Haanen, et al.
British Journal of Cancer
|
March 8, 2022
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis
Jesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
Data in Brief
|
November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Page
of 32